Year 2022 Vol. 30 No 1




Gomel State Medical University, Gomel,
Republic of Belarus

Objective. Development of a non-invasive assessing diagnostic and severity grading accuracy of portal hypertension in cirrhosis of the liver.
Methods. To identify diagnostically significant indicators, a statistical analysis of the data of laboratory and instrumental diagnostics was carried out in 60 patients with liver cirrhosis. The following biochemical indicators were determined: general and biochemical blood tests, coagulogram, general urine analysis; the level of interleukin-6 (IL-6), matrix metalloproteinases 1 and 9 (MMP-1, MMP-9), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), hepatocyte growth factor (HGF); abdominal ultrasound examination, esophagogastroscopy. The index of the ratio of the number of blood platelets (N×109 / L) to the transverse size (D) of the spleen in millimeters (PSR - Platelet count to Spleen diameter Ratio) was calculated: PSR = NTr / D spleen.
Results. The following indicators turned out to be diagnostically significant (predictive values based on ROC analysis are presented): blood levels of IL-6 (>19.9 pg/ml), MMP-1 (>8.06 ng/ml), cholesterol (≤4,5mmol/L), portal vein diameter (>13 mm), PSR (≤1.89). Diagnostic methods for cirrhosis and portal hypertension was developed, based on a point assessment of a set of laboratory and instrumental criteria (AUC = 0.931; p <0.001). The method can be used in a complex of medical services aimed at diagnosis of portal hypertension severity in patients with cirrhosis of the liver, as well as medical prevention of life-threatening complications of the disease.
Conclusion. The developed method makes it possible to identify patients with a severe form of portal hypertension, to recommend an unscheduled FEGDS with an endoscopic assessment of the risk of bleeding, and to carry out preventive and therapeutic procedures. If a low probability of a severe form of PH is identified, FEGDS should be refrained from if the patient has absolute or relative contraindications to the use of this diagnostic method.
The method can be used in a complex of medical services aimed at diagnosing the severity of portal hypertension against the background of liver cirrhosis.

Keywords: liver cirrhosis, portal hypertension, gastroesophageal varices, diagnosis of the disease severity
p. 20-27 of the original issue
  1. Ivashkin VT. Complications of portal hypertension in the liver cirrhosis Ros Fiziol Zhurn. 2009;95(10):1074-92. (In Russ.)
  2. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014 May 17;383(9930):1749-61. doi: 10.1016/S0140-6736(14)60121-5
  3. Kadirov R, Khadjibaev F. Endoskopic methods of gemostasis for bleeding of portal genesis The Scientific Heritage. 2020;(48-2):10-13. (In Russ.)
  4. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-35. doi: 10.1002/hep.28906
  5. De Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022
  6. Garbuzenko DV Neinvazivnye metody otsenki portalnoi gipertenzii u bolnykh tsirrozom pecheni. Poliklinika. 2015;(2):33-39. (In Russ.)
  7. Deng H, Qi X, Guo X. Diagnostic Accuracy of APRI, AAR, FIB-4, FI, King, Lok, Forns, and FibroIndex Scores in Predicting the Presence of Esophageal Varices in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Oct;94(42):e1795. doi: 10.1097/MD.0000000000001795
  8. Tuhbatullin MG, Ahunova GR, Galeeva ZM. Vozmozhnosti jehografii v diagnostike cirroza pecheni i portalnoj gipertenzii. Prakt Medicina. 2014;(3)):54-61. (In Russ.)
  9. Lyzikov AN, Skuratov AG, Shpakovsky YuP. Evaluation of the methods of imaging in the diagnosis of liver cirrhosis and portal hypertension Problemy Zdorovja i Jekologii. 2016;(2):21-25. (In Russ.)
  10. Shiina T, Nightingale KR, Palmeri ML, Hall TJ, Bamber JC, Barr RG, Castera L, Choi BI, Chou YH, Cosgrove D, Dietrich CF, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology. Ultrasound Med Biol. 2015 May;41(5):1126-47. doi: 10.1016/j.ultrasmedbio.2015.03.009
  11. Yada N, Kudo M, Morikawa H, Fujimoto K, Kato M, Kawada N. Assessment of liver fibrosis with real-time tissue elastography in chronic viral hepatitis. Oncology. 2013;84(Suppl 1):13-20. doi: 10.1159/000345884
  12. Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol. 2012 Mar;56(3):696-703. doi: 10.1016/j.jhep.2011.07.005
  13. Chen R, Deng H, Ding X, Xie C, Wang W, Shen Q. Platelet count to spleen diameter ratio for the diagnosis of gastroesophageal varices in liver cirrhosis: a systematic review and meta-analysis. Gastroenterol Res Pract. 2017;2017:7407506. doi: 10.1155/2017/7407506
  14. Chawla S, Katz A, Attar BM, Gupta A, Sandhu DS, Agarwal R. Platelet count/spleen diameter ratio to predict the presence of esophageal varices in patients with cirrhosis: a systematic review. Eur J Gastroenterol Hepatol. 2012 Apr;24(4):431-36. doi: 10.1097/MEG.0b013e3283505015
  15. Park SH, Park TE, Kim YM, Kim SJ, Baik GH, Kim JB, Kim DJ. Non-invasive model predicting clinically-significant portal hypertension in patients with advanced fibrosis. J Gastroenterol Hepatol. 2009 Jul;24(7):1289-93. doi: 10.1111/j.1440-1746.2009.05904.x
  16. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact. 2011 Sep 30;193(3):225-31. doi: 10.1016/j.cbi.2011.07.001
  17. Klinicheskij protokol Diagnostika i lechenie pacientov s zabolevanijami organov pishhevarenija: Postanovlenie Ministerstva zdravoohranenija Respubliki Belarus 54; 2017 Ijun 1 [Jelektronnyj resurs]. Rezhim dostupa: (In Russ.)
Address for correspondence:
246050, Belarus, Gomel,
Lange st. 5,
Gomel State Medical University,
the Department of Surgery No1 with the Course
of Cardiovascular Surgery,
tel.: +375447957922,
Skuratov Alexander G.
Information about the authors:
Skuratov Alexander G., PhD, Associate Professor of the Department of Surgery No.1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, Republic of Belarus.
Lyzikov Anatoly N., MD, Professor of the Department of Surgery No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, Republic of Belarus.
Mitsura Viktor M., MD, Associate Professor of the Department of Infectious Diseases, Gomel State Medical University, Gomel, Republic of Belarus.
Contacts | ©Vitebsk State Medical University, 2007-2023